Monday, 18 Jun 2018

You are here

Lupus Hospitalizations are Common

Patients with systemic lupus erythematosus (SLE) incur substantial morbidity and complications that may lead to hospitalizations and increased cost of lupus care. Researchers from the University Health Network in Toronto have published a review of SLE hospitalizations showing thta while commone (for either infection or lupus activity), only 2.8% of hospitalizations resulted in death.

They identified all SLE hospitalizations at University Health Network between 2011–2012 and 2013–2015 to assess cause, extent of hospitalizations, and outcomes. 

They identified 247 SLE patients with a total of 491 hospitalizations. Most (87.4%) were women, with an average age of 43.9 years, and a mean disease duration of 13.7 years.  Thus SLE patients was averaged 1.6 hospitalizations lasting 8.5 days.

Incidental causes, such as adverse drug reactions or pain, were the most common reason for admission (36.0%). Next most common were admissions were because of active SLE and infection (21.4% and 22.4%, respectively). ICU admission was required in 13% and 2.8% of hospitalizations resulted in death.

Fewer hospitalizations were seen in those who were employed, those on antimalarials or with higher educational level.

Damage related to lupus correlated with increased hospitalizations. and antimalarial use correlated with shorter length of stay. 

Re-hospitalization was seen in nearly 40% of patients. 

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The Microbiome and Lupus Connection Reviewed

In the current issue of the New England Journal of Medicine, Drs. James Rosenbaum and Gregg Silverstein review the pathogenesis of systemic lupus erythematosus (SLE) from the viewpoint of a dysbiolsis.

The complexity of the trillions of organisms that constitute our microbiome underscores its multiplicity of functions, including nutrient, metabolic and immune shaping functions.

SPAR Predicts ILD Progression in Systemic Sclerosis

The development and progression of interstitial lung disease in systemic sclerosis can be an ominous finding. A new analysis of two independent clinical trial cohorts shows that oxygen saturation (SpO2) < 94% after 6 minute walk time (6MWT) and the presence of arthritis predicted the development of ILD in SSc.

Low Disease Activity in Lupus Limits Damage

Patients with systemic lupus erythematosus (SLE) who were assessed as being in a low disease activity state during more than half of clinical visits had a decrease in organ damage events of approximately 50%, a retrospective study found.

Long Term Remission in SLE is Possible?

Researchers from the Toronto Lupus Clinic have described an atypical “monophasic” course in a small number (7.5%) of systemic lupus erythematosus (SLE) patients who achieved and sustained clinical remission, with most off of all medications for an average of 18 years.

Their inception SLE cohort includes patients enrolled within 18 mos of diagnosis.

Ustekinumab: A Novel Intervention in Giant Cell Arteritis

Treatment of refractory giant cell arteritis (GCA) with ustekinumab (Stelara) showed therapeutic promise as a steroid-sparing agent in a small, open-label study, Irish researchers reported.